KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) EBITDA Margin (2016 - 2025)

Pacific Biosciences Of California has reported EBITDA Margin over the past 16 years, most recently at 90.33% for Q4 2025.

  • Quarterly results put EBITDA Margin at 90.33% for Q4 2025, down 9349.0% from a year ago — trailing twelve months through Dec 2025 was 341.45% (down 14040.0% YoY), and the annual figure for FY2025 was 341.45%, down 14040.0%.
  • EBITDA Margin for Q4 2025 was 90.33% at Pacific Biosciences Of California, up from 98.47% in the prior quarter.
  • Over the last five years, EBITDA Margin for PACB hit a ceiling of 3.16% in Q4 2024 and a floor of 1146.92% in Q1 2025.
  • Median EBITDA Margin over the past 5 years was 195.57% (2021), compared with a mean of 238.29%.
  • Peak annual rise in EBITDA Margin hit 37614bps in 2025, while the deepest fall reached -94413bps in 2025.
  • Pacific Biosciences Of California's EBITDA Margin stood at 195.57% in 2021, then plummeted by -55bps to 303.03% in 2022, then skyrocketed by 55bps to 137.02% in 2023, then surged by 102bps to 3.16% in 2024, then plummeted by -2957bps to 90.33% in 2025.
  • The last three reported values for EBITDA Margin were 90.33% (Q4 2025), 98.47% (Q3 2025), and 105.73% (Q2 2025) per Business Quant data.